Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment

详细信息    查看全文

• 作者：Isabel Mir Viladrich^a ; ^{imir@hsll.es" class="auth_mail" title="E-mail the corresponding author} ; Esteban Daudé ; n Tello^b ; Guillermo Solano-Ló ; pez^b ; Francisco Javier Ló ; pez Longo^c ; Carlos Taxonera Samso^d ; Paquita Sá ; nchez Martí ; nez^e ; Xavier Martí ; nez Lacasa^f ; Mercedes Garcí ; a Gasalla^g ; Jordi Dorca Sargatal^h ; Miguel Arias-Guillé ; nⁱ ; José ; Maria Garcí ; a Garcí ; a^j
• 关键词：Chronic inflammatory diseases ; Latent tuberculosis infection ; Biologic therapies ; Interferon-gamma release assays
• 刊名：Archivos de Bronconeumología (English Edition)
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：52
• 期：1
• 页码：36-45
• 全文大小：1293 K

文摘

Tuberculosis risk is increased in patients with chronic inflammatory diseases receiving any immunosuppressive treatment, notably tumor necrosis factor (TNF) antagonists therapy. Screening for the presence of latent infection with Mycobacterium tuberculosis and targeted preventive treatment to reduce the risk of progression to tuberculosis disease is mandatory in these patients.

This Consensus Document summarizes the current knowledge and expert opinion of biologic therapies, including TNF-blocking treatments. It provides recommendations for the use of interferon-gamma release assays (IGRA) and tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection in these patients, and for the type and duration of preventive therapy.